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Abstract
Background: Previous studies have shown that human epidermal growth factor receptor 2 (HER2) may play an
important role in the invasion and metastasis of pancreatic cancer, but the relationship between HER2 amplification
level and prognosis of pancreatic cancer patients is still controversial. Therefore, we performed a meta-analysis to
determine the prognostic significance of HER2 amplification based on fluorescence in situ hybridization (FISH) in
patients with pancreatic cancer.
Methods: PubMed, EMBASE, and Web of Science (Jan 2001 to Jun 2015) were searched. Only articles that detect
the HER2 amplification by FISH method were included. RevMan 5.3 and STATA version 12 were used to perform
this meta-analysis. Pooled calculations were carried out on hazard ratio (HR) and 95 % confidence interval (CI) to
assess the risk of disease.
Results: A total of six eligible studies were enrolled in meta-analysis. The univariate analysis results showed that
HER2 amplification was not significantly associated with patients’ overall survival (pooled HR, 1.87, 95 % CI, 0.64–5.46,
P = 0.25), which are maintained in one study of multivariate analysis (HR 0.51, 95 % CI, 0.12–2.14, P = 0.358). HER2
amplification also had no correlation with clinicopathological factors such as age, gender, lymph node metastasis,
and tumor stage.
Conclusions: Our results showed that HER2 amplification based on FISH may not be a good prognostic factor
for survival in patients with pancreatic cancer.
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Background
Pancreatic cancer is the fourth leading cause of cancer
death in the USA [1]. With a 5-year survival rate of only
5 %, pancreatic ductal adenocarcinoma (PDAC) is known
for having an extremely poor prognosis [2]. The most
widely studied prognostic factors are related to patho-
logical characteristics of the pancreatic cancer, including
differentiation, tumor stage, and metastasis [3].
The progress we made in the field of gene research
can be specifically expressed as a continuous recognition
of new biological prognostic factors and provide refer-
ence for the development of cancer classification and
treatment strategies. The human epidermal growth fac-
tor receptor 2 (HER2) protein, the c-erb gene encoding
the epithelial growth factor receptor, has been consid-
ered to play an important role in tumorigenesis [4]. Early
studies showed that HER2 is expressed in many tissues
including breast, gastric, lung, and ovarian cancer and
may promote cell proliferation and facilitate uncontrolled
cell growth [5–7]. HER2 expression is observed in up to
30 % of breast cancer with this receptor being recognized
as a poor prognostic marker but also a therapeutic target
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of a herceptin-based therapy used in both the adjuvant
and metastatic setting. The patient’s treatment decisions
are increasingly dependent on the accurate detection of
HER2 expression.
Amplification of HER2 gene and/or overexpression of
HER2 protein have been implicated in the development
of pancreatic cancer (PC). The reported rates of HER2
overexpression in patients with PC range from 4 to 50 %
[8]. Until now, in patients with pancreatic cancer, whether
the amplification of HER2 may be a prognostic factor for
survival has been constantly investigated in numerous
studies worldwide. However, in contrast to breast cancer,
the association between HER2 amplification and the clini-
copathological characteristics of PC remains controversial,
with some studies suggesting that HER2 amplification is
associated with poor prognosis and others showing that it
is not an independent prognostic factor of patient out-
come [9, 10]. One important factor contributing to this
heterogeneity is that the methodologies for HER2 amplifi-
cation assessment and the criteria for positivity definition
varied a lot in different clinical studies.
In 90 % of pancreatic cancers, HER2 protein overexpres-
sion is attributable to gene amplification. The expression
of HER2 protein was detected by immunohistochemistry
(IHC) in routine practice because of simplicity and low
costs. IHC is the most widely used method for the assess-
ment of HER2 expression, which scores the membranous
immunostaining of the tumor cells ranging from 0 to 3+.
Adopting breast cancer scoring criteria for HER2 expres-
sion in PC would lead to many false-positive cases. HER2
gene amplification as detected by fluorescence in situ
hybridization (FISH) may be a reliable predictor of clinical
response to treatment of pancreatic cancer [11, 12].
Therefore, we performed this meta-analysis study to deter-
mine the prognostic significance of HER2 amplification
based on FISH in patients with pancreatic cancer.
Methods
Search strategy and study selection
All studies were searched using the keywords “HER2,”
“erbB-2,” or “HER2/neu” and “pancreatic neoplasms,”
“survival,” and “prognosis.” In the study, electronic search
engines were used for searching: PubMed, EMBASE, and
Web of Science (Jan 2001 to Jun 2015). Titles and ab-
stracts were reviewed for appropriate studies which
reported the association of HER2 amplification with
overall survival (OS) and clinicopathological features
in PDAC patients. The full texts of the studies were
reviewed to determine if they were relevant to our
aim. The reference lists of all articles were also reviewed
to identify additional eligible publications. All studies
included in this meta-analysis should meet the following
criteria: (1) patients with proven diagnosis of pancreatic
ductal adenocarcinoma, (2) HER2 amplification evaluation
using FISH method, (3) the clinicopathological character-
istics between HER2+ and HER2− patients were provided,
(4) OS were analyzed according to HER2 status, and (5)
the language used in publications was English. The follow-
ing was the exclusion criteria: (1) the relevant data could
not be extracted; (2) the correspondence letters, case re-
ports, and reviews; and (3) duplication of a previous publi-
cation. All research results were evaluated independently
by two reviewers (Xiaoping Li and Hua Zhao). All possible
publications were in the form of a full text to get further
assessment to meet the inclusion criteria. Any disagree-
ment was resolved by discussion.
Data extraction
Two researchers independently extracted the relevant
data from the literature. Data was extracted from the
primary publications according to the guidelines of the
Cochrane Handbook. Any disagreement was resolved by
discussion. Data retrieved from the publications included
the following: year of publication, first author’s name,
country, sample size, gender, age, disease stage, rate of
HER2 amplified, and survival data. The number of HER2
gene amplification was determined by FISH. The criteria
used for scoring HER2 by FISH in PDAC were as follows:
non-amplified, Her2:cep17 ratio <2; amplified, Her2:cep17
ratio ≥2. Two reviewers (Xiaoping Li and Hua Zhao)
assessed the quality of each study included in this meta-
analysis using the Critical Appraisal Skills Programme
(CASP) assessment tool and the definitions of the seven
items for reporting study quality provided by Azami-
Aghdash et al. [13]. Most articles compiled in this study
had a good quality score. Staging of pancreatic cancer was
based on the UICC classification revised in 2012 [14]. The
software GetData Graph Digitizer 2.24 (http://getdata-
graph-digitizer.com/) was applied to digitize and extract
the data from the Kaplan-Meier curve in some articles.
Statistical analysis
The software RevMan 5.3 (the Cochrane Collaboration,
Copenhagen) and STATA version 12.0 software (Stata
Corporation, College Station, TX, USA) were employed.
Comparisons of dichotomous measures were performed
to calculate odds ratios (ORs) and their 95 % confidence
interval (CI). For the pooled analysis of HER2 expression
on survival outcome, hazard ratios (HRs) and its 95 %
CIs were the recommended summary statistics for meta-
analysis of OS. Heterogeneity was assessed using the I2
test and Q test. I2 > 50 % indicated significant heterogen-
eity. Meta-analysis of the data using a fixed-effect model
was performed when I2 tests showed no heterogeneity;
otherwise, a random-effect model was used. Two or more
than two HER2 studies were identified for meta-analysis,
while descriptive analysis is performed in the rest of the
studies. P < 0.05 was considered as statistically significant.
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Publication bias was assessed by directly assessing the
asymmetry of Begg’s funnel plot, and the quantitative evi-
dence was provided by Egger’s test. Sensitivity analysis was
also conducted to examine the stability of the results.
Results
Study characteristics
We identified 459 studies initially eligible for inclusion
based on title and abstract screening. After scrutinizing
the abstracts, 18 full-text articles were chosen. After fur-
ther eligibility assessment, 12 articles were further ex-
cluded, including two due to survival data not available
based on HER2 grouping and ten using only IHC or
DISH for HER2 detection (Fig. 1). Finally, we identified
six studies from five countries, which used FISH method
to detect the HER2 status and provided outcome data
stratified by HER2 status. The main characteristics of
the six literatures are summarized in Table 1 [9, 10, 15–18].
The total number of pancreatic cancer patients included
was 752. Among these studies, one study was performed in
China, one in Australia, two in the USA, and two in
Germany. All included studies were retrospective cohort
studies. According to the CASP quality criteria, most of
them were of high quality.
Correlation between HER2 amplification and
clinicopathological parameters
We investigated the association of HER2 amplification
status with clinicopathological parameters. The amplified
rates of HER2 in the six studies ranged from 2.1 to
23.8 % (Table 1), with a pooled rate of 7.7 % (58/752).
The correlation of HER2 amplification with clinico-
pathological parameters was then studied (Table 2).
Three studies reported data on age. Compared with
younger patients (≤60 years), pooled data showed that
elder patients (>60 years) did not show HER2 amplifi-
cation (OR 0.71, 95 % CI 0.10–5.21, P = 0.74). Further-
more, five studies reported data on gender, two studies
reported data on tumor location, six studies reported
data on tumor differentiation, four studies reported
data on lymph node metastasis, two studies reported
data on T stage, and four studies reported data on
TNM classification and their relationship with HER2
amplification. When the data was pooled, respectively,
there were no significant associations between HER2
amplification and gender (P = 0.49), tumor location
(P = 0.12), differentiation (P = 0.55), lymph node me-
tastasis (P = 0.76), T stage (P = 0.16), and TNM stage
(P = 0.89) (Table 2).
Fig. 1 Flow diagram of selection process to identify eligible studies
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Correlation between HER2 amplification and survival
outcome
We evaluated the correlation between HER2− amplification
and survival in a panel of 642 patients from five studies.
Meta-analysis on the association of HER2 amplification
with OS in patients with PC was carried out. A total of four
studies reported OS data in univariate analysis, including
one study reporting on OS both in univariate and
multivariate analysis. One study reported only RFS data
in univariate analysis. Among these pieces of research,
two studies found no significant correlation between
HER2− amplification and OS, whereas two studies showed
that HER2 amplification was a significant association with
patients’ prognostic outcomes. Meta-analysis of the four
univariate analysis showed that HER2 amplification
was not associated with OS (HR 1.87, 95 % CI, 0.64–5.46,
P = 0.25) (Fig. 2). However, there was significant hetero-
geneity between the four univariate studies (P < 0.0001,
I2 = 87 %). One study reported no significant correl-
ation between HER2− amplification and RFS (HR 0.93,
95 % CI, 0.49–1.78, P = 0.823). Compared with tumors
without HER2 amplification, those with HER2 amplifi-
cation were not associated with a statistically significant
difference in OS by multivariate analysis (HR 0.51,
95 % CI, 0.12–2.14, P = 0.358).
Sensitivity analysis and publication bias
Sensitivity analysis to assess the potential impact of each
study on pooled HR values was conducted. Results showed
that the corresponding combined HR did not change
significantly at each step, but the potential heterogeneity
was observed again. We further limited the scope of our
analysis; quality scores for A were included for meta-
analysis. The results showed that HER2 amplification was
not significantly associated with OS, and no significant
heterogeneity existed (P = 0.76). Publication bias was
assessed by Begg’s funnel plot and Egger’s test. The results
of the funnel plot (Fig. 3) and Egger’s test showed that
evidence for symmetry and publication bias did not
exist (P = 0.723, Fig. 4).
Discussion
During tumorigenesis, HER2 has been identified as an
oncogene involved in the regulation of proliferation, in-
vasion, and apoptosis of tumor cells. A recent report
showed that about 42 % of HER2-positive staining and
16 % HER2 gene amplification were observed in pancreatic
cancer tissue samples [19]. The expression and amplifica-
tion of HER2 in various tumor cells not only suggests a
poor prognosis but also can be used as an indicator of the
corresponding targeted therapy. Preclinical studies showed
that the monoclonal antibody trastuzumab can significantly
inhibit the growth of pancreatic cancer cell lines and
xenograft tumor models [20–22].
Nowadays, IHC is a common method for the determin-
ation of HER2 in pancreatic cancer tissues. A major prob-
lem with the IHC scoring system for pancreatic cancer is
that the morphological and biological characteristics of
breast cancer and pancreatic cancer are quiet different.
Antigen-retrieval protocols optimized for breast tissue
are not necessarily appropriate for pancreas, and some
cases did show some membrane labeling in nonmalignant
Table 1 Main characteristics of all studies included in the meta-analysis
Study Country No. patients (M/F) Age (years) HER2-positive rate (%) Follow-up period Quality score
Dancer 2007 [15] USA 38 (3/25) Median 62 (34–82) 10.7 NA B
Stoecklein 2004 [9] Germany 50 (28/22) NA 24 Median 13 months (3–99) A
Luo 2013 [18] China 114 (17/97) NA 14.9 NA B
Sharif 2008 [16] USA 63 (NA) Mean 67 (28–85) 23.8 NA A
Saxby 2005 [10] Australia 30 (17/13) Median 68 (39–82) 3.3 Median 1.7 years B
Chou 2013 [17] Australia 469 (241/228) Median 68 (28–88) 2.1 NA A
M/F male/female, NA unknown
Table 2 Meta-analysis of HER2 amplification in patients with pancreatic cancer
Clinicopathological parameters No. of studies Cases Model OR 95 % CI P value for OR P value for heterogeneity
Age (≤60/>60) 3 172 R 0.71 0.10–5.21 0.74 0.12
Gender (male/female) 5 691 F 1.25 0.66–2.36 0.49 0.60
Location (head/other) 2 556 R 7.58 0.60–95.35 0.12 0.08
Differentiation (well + moderate/poorly) 6 726 F 0.81 0.42–1.60 0.55 0.33
Lymph node metastasis (yes/no) 4 696 F 1.10 0.59–2.07 0.76 0.96
T stage (T1 + T2/T3 + T4) 2 86 F 0.74 0.34–1.62 0.16 0.45
TNM (I + II/III + IV) 4 645 R 0.87 0.14–5.63 0.89 0.04
OR odds ratio, CI confidence interval, F fixed-effect model, R random-effect model
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elements, suggesting that the antigen-retrieval process
may have been set too high. This may explain that IHC
methods have the potential to overestimate HER2-positive
status. The other technique is FISH, which is mainly to
detect the level of HER2 gene amplification. Precise
and accurate detection of HER2 gene expression is cru-
cial in pancreatic cancer to determine the future course
of treatment [15].
In this study, we investigated the relationship between
the amplification levels of HER2 and clinicopathological
factors by meta-analysis. Dysfunction could potentially
occur independently at any level in the manufacture of
the HER-2 protein such that overexpression exists on
the cell surface without genetic amplification. Transla-
tional and transcriptional dysfunction has been implicated
in other cancer processes to explain this phenomenon.
Therefore, such problems will lead to overtreatment or
undertreatment by Herceptin. The accuracy of the copy
number and the amplification level of HER2 will be of
greater clinical significance for Herceptin therapy. This de-
termines whether the technique is trustable or reliable. In
pancreatic cancer, Safran et al. [23] addressed this issue in
a subset of the IHC group (n = 11), finding only three of
eight 2+ tumors had gene amplification and none in three
3+ tumors. The finding in this study was in better
agreement with FISH than IHC and supports the idea that
FISH displays the functional activity of HER-2 gene
expression.
In contrast to previous reports, our results showed that
HER2 amplification was not related to poor prognosis of
pancreatic cancer. There was no statistically significant
relationship between HER2 amplification and clinico-
pathological variables (gender, age, tumor size, grade of
differentiation, T stage, and TNM stage). The reasons
resulting in this contrary mainly lie in the different cri-
teria for publication selection and enrollment. This study
only enrolled the publications that define HER2 status
with FISH method, whereas the previous studies used
various methods for HER2 detection and scoring.
The significant variability of HER2 amplification defin-
ition makes the results incomparable from one study to
another. The sample quality and antibody might be im-
portant for the difference in FISH positivity. The prog-
nostic significance changes even in the same population
if different criteria are used to distinguish HER2+ and
HER2− patients. In this study, all included studies define
HER2 status with the same criteria (Her2:cep17 ratio ≥2
as the threshold for amplified), which guarantees the
credibility of this study. Hofmann et al. [24] proposed a
modified HER2 scoring system; the definition for HER2
Fig. 2 Forest plot of the association between HER2 amplification and OS of pancreatic cancer
Fig. 3 Begg’s funnel plot for visual assessment of publication bias for HER2 amplification and OS of pancreatic cancer
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positivity has changed from previous IHC 2+ or 3+ or
HER2 amplification to IHC 3+ or IHC 2+ with HER2
amplification. The principle of this method involves IHC
test for HER2 first, furthered by FISH for IHC 2+ patients.
The American Society of Clinical Oncology/College of
American Pathologists had recommended an updated test-
ing criterion to define HER2-positive status for breast cancer
in 2013 [25]. HER2-positive status was defined as follows:
there is evidence of protein overexpression (IHC) or gene
amplification (HER2 copy number or HER2/CEP17 ratio) by
FISH based on counting at least 20 cells within the
area. But most reports in our study did not use this
criterion; patients received FISH detection directly, so
false positive might have existed. Adopting a uniform
HER2 amplification definition may be helpful for clinical
decision-making in the administration of trastuzumab.
Overexpression of HER2 in breast cancer often indicates
a poor prognosis. Different from breast cancer, the role of
HER2 as a prognostic factor for pancreatic cancer is still
controversial. Saxby et al. [10] suggested that HER2 overex-
pression was significantly associated with worse prognosis.
Chou et al. [17] carried a study included 469 pancreatic
cancer patients and got the opposite result. However, in
most of the literature, there was little correlation between
HER2 amplification and poor prognosis for pancreatic can-
cer. Our results showed that an HER2-amplification status
was not related to the prognosis of pancreatic cancer, and it
suggested that the HER2 amplification may not act as a
prognostic factor for OS in pancreatic cancer.
The prognosis of PC depended on many clinicopatho-
logical factors such as tumor size, location, lymph node
metastasis, stage, differentiation degree, etc. Of these
factors, tumor size, location, lymph node metastasis, and
tumor stage seem to be most important. In Chou’s study
[17], they reported that no correlation was found between
HER2 amplification and T- or N-factors or TNM stage.
Our results also confirmed this. In a series of 30 pancre-
atic cancers, Saxby et al. [10] reported a general trend of
increased HER2 amplification with tumor stage. However,
this study included small number patients. Moreover, we
also found that there is not much evidence indicating
HER2 amplification as a prognostic factor for worse out-
come, this also supports the putative role of HER2 in
tumor cell aggressiveness but only as a secondary event.
We hope to get more information from a larger sample of
studies in order to better understand the accuracy of the
treatment in the future.
Using anti-HER2 drugs for HER2-positive patients can
greatly improve the efficacy of conventional chemother-
apy. Harder et al. [26] carried a phase II trial to assess the
efficacy and safety of Xeloda and trastuzumab as first-line
therapy in patients with HER2-positive metastatic pancre-
atic cancer. The results showed that the treatment was
well-tolerated; however, PFS and OS had no obvious ad-
vantages compared with standard chemotherapy. Further
research is required to explain the impact of anti-HER2
therapy on the prognosis of metastatic pancreatic cancer.
There are some limitations of this study that should be
considered. Firstly, the studies data included in this
meta-analysis were all retrospective and nonrandomized
ones, so the results may be limited for they are not the
highest quality of evidence. Secondly, we cannot rule out
that publication bias or heterogeneity between studies
may lead to an underestimate of the correlations. Thirdly,
we could not get enough data for subgroup analysis such
as tumor stage, age, and gender from most of the included
studies. Therefore, the prognostic value of HER2 amplifi-
cation is not clear in subtypes of pancreatic cancer. The
software GetData Graph Digitizer was applied to digitize
and extract the data from the Kaplan-Meier curve in some
Fig. 4 Egger’s publication bias plot showed no publication bias for studies regarding HER2 and OS of pancreatic cancer
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articles. This may have led to bias and might not allow a
reliable conclusion. Fourthly, the study was restricted to
studies published as a full-text article in English, which
may lead to bias. Lastly, most reports in this study used
FISH detection directly, so we did not know the results of
the concordance between IHC and FISH and false positive
might have existed.
Conclusions
In summary, we showed that HER2− amplification based
on FISH was not related to clinicopathological features
of PC and also not associated with the survival of the pa-
tients. As the prognostic value of HER2 for pancreatic
cancer is low, anti-HER2 therapy may not be a good
choice for pancreatic caner. This can help us to make a
decision for optimizing a therapeutic scheme. To further
validate our results, larger sample size and well-designed
studies are needed to better investigate the prognostic
significance of HER2 amplification in pancreatic cancer.
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